EFFICACY OF LISINOPRIL IN CHRONIC KIDNEY DISEASE


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The paper considers the results of controlled clinical trials evaluating the efficacy of lisinopril in the prevention of cardiovascular and renal outcomes in patients with arterial hypertension, including those with chronic kidney disease, as well as the nephroprotective properties of the drug in patients with diabetes mellitus and nondiabetic nephropathies.

Full Text

Restricted Access

About the authors

S. Moiseev

L. Strlzhakov

References

  1. Holtkamp F., de Zeeuw D., Thomas M. et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function // Kidney Int. - 2011; 80: 282-7.
  2. Леонова М.В., Белоусов Д.Ю. Аналитическая группа исследования Пифагор. Первое российское фармакоэпидемиологическое исследование артериальной гипертонии // Качественная клин. прак. - 2002; 3: 47-53.
  3. Swan S., Olyaei A., Sica D. Clinical pharmacology for the nephrologist // Neph. Sap. - 2010; 9: 220-64.
  4. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure WorkGroup. KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease // Kidney Int. -2012; 2: 337-414.
  5. Mafham M., Emberson J., Landray M. et al. Estimated glomerular filtration rate and the risk of major vascular events and all-cause mortality: a meta-analysis // PLoS One. - 2011; 6 (10): e25920.
  6. Подзолков В.И., Осадчий К.К. Ингибиторы АПФ в лечении артериальной гипертензии: фокус на лизиноприл // РФК. - 2009; 1: 57-62.
  7. Malacco E., Santonastaso M., Vari N. et al. Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with lisinopril (PREVAIL) study // Clin. Ther. - 2004; 26 (6): 855-65.
  8. Rahman M., Brown C., Coresh J. et al. ALLHAT Collaborative Research Group The prevalence of reduced glomerular filtration rate in older hypertensive patients and its association with cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment Prevent Heart Attack Trial // Arch. Intern. Med. -2004; 164 (9): 969-76.
  9. Rahman M., Pressel S., Davis B. et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and LipidLowering Treatment до Prevent Heart Attack Trial (ALLHAT) // Arch. Intern. Med. - 2005; 165 (8): 936-46.
  10. Rahman M., Ford C., Cutler J. et al. ALLHAT Collaborative Research Group. Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment до Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR // Clin. J. Am. Soc. Nephrol. - 2012; 7 (6): 989-1002.
  11. Barzilay J., Davis B., Cutler J. et al. ALLHAT Collaborative Research Group. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized до receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment до Prevent Heart Attack Trial (ALLHAT) // Arch. Intern. Med. - 2006; 166 (20): 2191-201.
  12. Whelton P., Barzilay J., Cushman W. et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment до Prevent Heart Attack Trial (ALLHAT) // Arch. Intern. Med. - 2005; 165: 1401-9.
  13. Agha A., Amer W., Anwar E. et al. Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: A randomized controlled trial // Saudi J. Kidney Dis. Transpl. - 2009; 20: 429-35.
  14. ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensinconverting enzyme inhibitors? A meta-analysis of individual patient data // Ann. Intern. Med. - 2001; 134: 370-9.
  15. Marre M., Lievre M., Chatellier G. et al. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study) // BMJ. - 2004; 328: 495.
  16. Ravid M., Lang R., Rachmani R. et al. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study // Arch. Intern. Med. - 1996; 156: 286-9.
  17. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group // Lancet. - 1997; 349 (9068): 1787-92.
  18. Crepaldi G., Carta Q., Deferrari G. et al. Effects of lisinopril and nifedipine on the progression до overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. The Italian Microalbuminuria Study Group in IDDM // Diabetes Care. - 1998; 21 (1): 104-10.
  19. Tarnow L., Rossing P., Jensen C. et al. Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy // Diabetes Care. - 2000; 23 (12): 1725-30.
  20. Schjoedt K., Astrup A., Persson F. et al. Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial // Diabetologia. - 2009; 52 (1): 46-9.
  21. Maschio G., Alberti D., Janin G. et al. For the Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency // N. Engl. J. Med. - 1996; 334: 939-45.
  22. Ruggenenti P., Perna A., Gherardi G. et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy // Lancet. - 1998; 352: 1252-6.
  23. Ruggenenti P., Perna A., Gherardi G. et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria // Lancet. - 1999; 354: 359-64.
  24. Jafar T., Schmid C., Landa M. et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data // Ann. Intern. Med. - 2001; 135: 73-87.
  25. Bakris L. Slowing nephropathy progression: focus on proteinuria reduction // Clin. J. Am. Soc. Nephrol. - 2008; 3 (Suppl. 1): 3-10.
  26. Kosmadakis G., Filiopoulos V., Georgoulias C. et al. Comparison of the influence of angiotensin-converting enzyme inhibitor lisinopril and angiotensin II receptor antagonist losartan in patients with idiopathic membranous nephropathy and nephrotic syndrome // Scand. J. Urol. Nephrol. - 2010; 44 (4): 251-6.
  27. Janssen J., Gans R., van der Meulen J. et al. Comparison between the effects of amlodipine and lisinopril on proteinuria in nondiabetic renal failure: a double-blind, randomized prospective study // Am. J. Hypertens. - 1998; 11 (9): 1074-9.
  28. Nakanishi K., Iijima K., Ishikura K. et al. Efficacy and safety of lisinopril for mild childhood IgA nephropathy: a pilot study // Pediatr. Nephrol. - 2009; 24 (4): 845-9.
  29. Amara A., Sharma A., Alexander J. et al. Randomized controlled trial: lisinopril reduces proteinuria, ammonia, and renal polypeptide tubular catabolism in patients with chronic allograft nephropathy // Transplantation. - 2010; 89 (1): 104-14.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies